Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
-Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had excellent oral bioavailability, drug exposure and a half-life of up to 12 hours. These data support ASC30_39 FDC tablets...
Swiss Re Independently Validates 25:1 Return on Investment for Cancer Rehabilitation. Osara Health Delivered 91% of the Program Data.
Osara Health discloses its role as the primary cancer support provider in Swiss Re's independent Rehabilitation Watch 2025 report, which confirmed a 25:1 return on investment and the highest return-to-work rate of any condition at 71%. NEW YORK, April 7, 2026 /PRNewswire/ -- Swiss Re's Rehabilitation Watch 2025 has confirmed a 25:1...
Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
HONG KONG, April 7, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter Phase Ib/II study evaluating cadonilimab in combination with anlotinib and docetaxel in patients with locally advanced or...
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026). Q1 2026 Highlights Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter. ...
NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, April 6, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. AI...
Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression
By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a more cost-effective and reimbursement-aligned treatment model. TAICHUNG, April 6, 2026 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announced the positive results...
GC Biopharma Enhances IVIG Safety Profile with Advanced Prothrombotic Impurity Detection Technology
Proprietary analytical method for precise Factor XI (FXI) measurement published in the Journal of Microbiology and Biotechnology Novel IgG Blocker eliminates heterophilic antibody interference, ensuring clinical-grade purity and mitigating thromboembolic risks YONGIN, South Korea, April 6, 2026 /PRNewswire/ -- GC Biopharma (006280.KS), a global leader in plasma-derived protein therapies, today...
The 93rd CMEF is set to open in Shanghai, as the world’s largest medical device industry exhibition spotlights AI, robotics, and international cooperation
SHANGHAI, April 5, 2026 /PRNewswire/ -- The 93rd China International Medical Equipment Fair (CMEF) will be held from April 9 to 12 at the National Exhibition and Convention Center (NECC) in Shanghai. As the largest global medical device industry chain exhibition, this year's event under the theme of "Innovation Fusion, Boundless Evolution," will focus on cutting-edge technologies and international...
Ridgetech, Inc. Announces 1-for-150 Reverse Share Split
HANGZHOU, China, April 4, 2026 /PRNewswire/ -- Ridgetech, Inc., a Cayman Islands exempted company (the "Company") (Nasdaq: RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that it expects to implement a 1-for-150 reverse share split on its ordinary shares ("Ordinary Shares") effective Tuesday, April 7, 2026 at 5:00 p.m. Eastern Time, with trading to...
Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform
HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics. Covalent small-molecule drugs have shown great success...
